Ts'ao C, Neofotistos D, Oropeza M, Vahabinejad S, Finn W G
Department of Pathology, Northwestern Memorial Hospital, Chicago, Illinois 60611, USA.
Am J Hematol. 1997 Mar;54(3):214-8. doi: 10.1002/(sici)1096-8652(199703)54:3<214::aid-ajh7>3.0.co;2-z.
A single point mutation of the factor V (FV) gene, leading to the substitution Arg506Gln in the FV molecule (FV-Leiden) and hence resistance to its breakdown by activated protein C (APC), is the most prevalent risk factor for venous thrombosis in the Caucasians. A ratio determined by activated partial thromboplastin time (APTT) of test plasma in the presence or absence of exogenous APC (the APC ratio), is the method widely used to screen individuals with this risk factor for thrombosis. Because of functional defects of vitamin K-dependent clotting factors in patients on oral anticoagulant therapy, this method cannot be applied to those patients without modification. One modification is to mix test plasma (1:5 or 1:10) with FV-deficient plasma so that 80-90% of functioning vitamin K-dependent factors are supplied by the FV-deficient plasma. Even with 10-20% of FV in the mixture, APC-resistance still can be demonstrated. In this report, we present our results of the modified APC-sensitivity assay using FV-deficient plasma from different commercial sources. APC ratios determined by the original method in which test plasma is not mixed with FV-deficient plasma can be significantly different from those determined by the modified method in which test plasma is diluted 1:5 with FV-deficient plasma. This difference between methods was observed not only in normal individuals, but also in FV-Leiden positive individuals, and in patients on warfarin therapy. Further, APC ratios varied significantly depending on the commercial source of the FV-deficient plasma. The modified method is apparently suitable to identify APC-resistance in patients on warfarin therapy, as well as in individuals not receiving anticoagulant treatment. However, one must be aware that APC-resistance ratios obtained with the modified method are likely to be different from those established with the original method, and the source of FV-deficient plasma can be a factor influencing the ratios in the former cases.
凝血因子V(FV)基因的单点突变导致FV分子中的精氨酸506被谷氨酰胺取代(FV-莱顿),从而使其对活化蛋白C(APC)的降解产生抗性,这是白种人静脉血栓形成最常见的危险因素。通过在有或没有外源性APC的情况下检测血浆的活化部分凝血活酶时间(APTT)所确定的比率(APC比率),是广泛用于筛查具有这种血栓形成危险因素个体的方法。由于口服抗凝治疗患者中维生素K依赖性凝血因子存在功能缺陷,该方法未经修改不能应用于这些患者。一种改进方法是将检测血浆(1:5或1:10)与FV缺乏血浆混合,以便80-90%的功能性维生素K依赖性因子由FV缺乏血浆提供。即使混合物中含有10-20%的FV,仍可证明存在APC抗性。在本报告中,我们展示了使用不同商业来源的FV缺乏血浆进行改良APC敏感性测定的结果。通过原始方法(检测血浆不与FV缺乏血浆混合)测定的APC比率与通过改良方法(检测血浆用FV缺乏血浆按1:5稀释)测定的APC比率可能有显著差异。这种方法间的差异不仅在正常个体中观察到,在FV-莱顿阳性个体以及接受华法林治疗的患者中也观察到。此外,APC比率根据FV缺乏血浆的商业来源而有显著差异。改良方法显然适用于识别接受华法林治疗的患者以及未接受抗凝治疗个体中的APC抗性。然而,必须注意的是,用改良方法获得的APC抗性比率可能与用原始方法确定的比率不同,并且FV缺乏血浆的来源可能是影响前一种情况下比率的一个因素。